Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 85%
filed 2026-06-26
Item 5.02
Darren E. Guidry was appointed President of Home Bancorp, Inc. effective July 1, 2026, representing a significant promotion from Chief Risk Officer. While the disclosure also mentions compensatory arrangements (salary increase to $384,000), the principal disclosed action centers on the appointment to a new executive role and the structural reorganization separating CEO and President functions. This is material to investors as it reflects a material change in the Company's leadership structure and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-06-26
Item 5.02
Fortrea appointed Jason F. Knoblauch as Chief Financial Officer effective July 6, 2026, succeeding Jill McConnell. Knoblauch's compensation package includes a base salary of $570,000, target bonus of 85%, an inducement award of $1,250,000, and equity grants totaling approximately $4,000,000 in RSUs and PSUs.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
Item 5.02
The disclosure centers on the appointment of Matt Aune as Chief Financial Officer effective June 22, 2026. While the filing also includes compensatory details (base salary of $237,000 and a stock option grant of 1,500,000 shares), the principal disclosed action is the appointment of a named executive to a principal officer role. The compensation is ancillary to the appointment event itself.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-26
Item 5.02
Dara Bazzano was appointed as Robinhood's principal accounting officer effective June 25, 2026, a key executive role responsible for accounting, tax, financial operations, financial reporting, and internal control functions. While the disclosure also mentions that Shiv Verma ceased serving as principal accounting officer (retaining his CFO role), the principal disclosed action is the appointment of a new principal accounting officer with significant compensation details ($425,000 base salary, $1.54M equity target, $3.3M RSU grant, and $400,000 sign-on bonus), making this an executive appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
Item 5.02
The filing discloses the appointment of Ms. Stephanie Wei-Ni Wen to the Board of Directors effective June 24, 2026. The Board explicitly states it believes her extensive transactional and legal experience qualifies her for the role. This is a clear director appointment under Item 5.02, which is material to investors as board composition affects governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-25
Item 5.02
The disclosure centers on the election of Doug Petno and Troy Rohrbaugh as Co-Presidents of JPMorgan Chase, with Petno becoming sole CEO of CIB and Rohrbaugh becoming CEO of CCB. While the filing also includes compensatory arrangements (equity awards) and a departure (Marianne Lake's retirement), the principal action disclosed is the appointment of two executives to major leadership roles. The succession planning context and the prominence given to the promotions support classification as exec_appointment rather than exec_compensation, though the compensation component is material and secondary.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-25
Item 8.01
The disclosure centers on the appointment of Carlos Adrian Gruebler as principal accounting officer and Vice President and Chief Accounting Officer of TMCC, effective June 29, 2026. While Brittany Baird's concurrent resignation is mentioned, the principal action disclosed is Gruebler's appointment to a key financial leadership role. The principal accounting officer is a material executive position affecting financial reporting oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
Maria Milagros Paredes was appointed as Chief Financial Officer and Corporate Secretary of Lion Copper & Gold Corp. effective June 22, 2026, succeeding Lei Wang. The appointment includes material compensatory arrangements comprising a US$200,000 base salary, 2.5 million options with various vesting conditions, and severance protections.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
AeroVironment appointed William J. Lynn III to its Board of Directors, effective June 24, 2026. Lynn is a prominent defense industry executive with extensive government and national security experience, including prior service as U.S. Deputy Secretary of Defense and CEO of Leonardo DRS.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
Archrock appointed Mohit Singh as Senior Vice President and Chief Financial Officer, effective July 6, 2026. Singh brings 25+ years of energy industry experience, including prior roles as CFO of Chesapeake Energy and senior leadership at BP and Goldman Sachs. The appointment includes substantial compensatory arrangements ($650,000 base salary, $2.3M annual equity target, $1.5M sign-on award).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-25
Item 5.02
The filing discloses two executive appointments: Gregory S. Patton was appointed Chief Executive Officer and Board member (promoted from CFO), and Michael Shelly was appointed Executive Vice President and Chief Financial Officer. While the disclosure also includes compensatory arrangements (employment agreements, equity awards, and PSU amendments), the principal disclosed action centers on these two appointments to key leadership roles. The appointment of a new CEO is a material governance event affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
Jonathan J. Mazelsky was appointed as a Class II director of Insulet Corporation, effective July 1, 2026. Mazelsky brings significant executive experience, including 14 years at IDEXX Laboratories where he served as President and CEO, and prior leadership roles at Philips and Agilent.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-25
Item 5.02
The company appointed Gilbert E. Nathan and Michael J. Wartell as independent directors and appointed Marie Persichetti as Chief Financial Officer effective August 1, 2026, replacing Jonathan Collins who resigned effective July 31, 2026. These appointments were made in accordance with the company's obligations under the Credit Agreement amendment and include detailed compensation and retention arrangements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-25
Item 5.02
The filing discloses the appointment of Pratik Trivedi as President and CEO effective July 6, 2026, along with his appointment to the Board, which is the principal disclosed action. While the filing also covers Kieran O'Sullivan's transition to Executive Chairman (a departure from CEO), the substantive focus and forward-looking impact center on Trivedi's appointment to the top executive role, including detailed compensation terms ($675,000 base salary, $2.15M long-term incentive award, and change-in-control severance provisions). This is a material executive succession event affecting investor assessment of company leadership.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-25
EX-99.1
The exhibit is a Material Change Report (Form 51-102F3) announcing the appointment of Richard Pozzebon as Chief Financial Officer of Titan Mining Corporation, effective July 6, 2026. The appointment of a named executive officer to a C-suite position is a material governance event that would affect a reasonable investor's assessment of the company's leadership and financial oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
Two new directors, Laura Gentile and Marc Maurer, were appointed to the Board effective immediately following the 2026 annual meeting, increasing the Board size from 9 to 11 members pursuant to a previously disclosed Cooperation Agreement with Dennis J. "Chip" Wilson and related entities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-25
Item 7.01
Paul Kazarian has been appointed President and Principal Executive Officer of ASA Gold & Precious Metals Limited, representing a material change in the company's leadership. While the disclosure also mentions the departure of Axel Merk and Peter Maletis and the establishment of an interim investment committee, the principal action disclosed is the appointment of a new PEO, which is a significant governance event affecting investor assessment of company leadership and direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
Boyd Gaming appointed two new independent directors, Stacia J. Andersen and George C. Roeth, to its Board of Directors effective June 22, 2026. Both appointees are experienced executives from major public companies (PetSmart, Abercrombie & Fitch, Central Garden and Pet, and Clorox) and qualify as independent under NYSE listing standards.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
Peter Bell was elected to the Board of Directors effective June 23, 2026, and appointed as Chair of the Nominating and Corporate Governance Committee. The Board expanded from four to five members to accommodate this appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-25
The filing discloses the appointment of Ralph Venegas as Principal Financial Officer and Acting Chief Financial Officer of Laser Photonics, effective June 24, 2026. While the filing also mentions termination of the prior CFO arrangement with Roman Franklin/CFO Portal, the principal disclosed action centers on the appointment of a new CFO with detailed background information provided. This is a material executive appointment affecting the company's financial leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
The filing discloses three executive appointments effective June 18, 2026: Judah Korman as Chief Operating Officer, Zack Wilder as Chief Technology Officer, and Mordy Beyman as Vice President (later described as Executive Vice President in the press release). These are material leadership changes at a public company, with detailed biographical information and compensation arrangements disclosed under Item 5.02. The appointments are central to the company's stated strategic pivot toward AI-powered insurance products and agency roll-up operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
The filing discloses the appointment of Steven N. Gordon as Chief Operating and Administrative Officer and Board member, and K. Harold Fletcher as Chief Legal and Strategy Officer and Corporate Secretary, both effective June 19, 2026. These are material executive appointments to senior leadership roles that would affect investor assessment of the company's governance and operational structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
NeoGenomics appointed Carolyn S. Starrett as a director to fill a newly created board vacancy, effective June 23, 2026. Ms. Starrett brings 25+ years of executive experience, including a decade as CEO of Flatiron Health and prior roles at Foundation Medicine and Boston Consulting Group, making this a material addition to the Board's composition and expertise.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-06-25
Item 5.02
Patrick Keenan was appointed as Chief Financial Officer of AlTi Global, Inc., effective July 1, 2026, promoted from Deputy CFO. The appointment follows the planned retirement of Michael Harrington and includes a compensation package of $375,000 salary plus $450,000 target bonus.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
Ryan Schneider was appointed as a Class III director to Affirm's Board effective July 1, 2026, and appointed to the Audit Committee and Nominating and Governance Committee, bringing significant executive experience from his prior roles as CEO of Anywhere Real Estate and President of Card Business at Capital One.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
Sudhanshu Priyadarshi was appointed as Chief Financial Officer and President, International, effective June 25, 2026. The appointment includes compensatory arrangements with a base salary of $900,000, target bonus of 115%, and equity awards totaling $7,000,000. Tom Fitzgerald's role as Interim CFO concluded with this appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-25
Item 5.02
The filing discloses both the resignation of Ms. Dandan Chen as Director and CEO and the election of Liao Xiu Ze as CEO. While both events occur, the principal disclosed action centers on the appointment of a new CEO—Liao Xiu Ze was elected to the CEO role in addition to his existing CFO, Treasurer, and Secretary positions. This is a material leadership transition affecting the company's chief executive officer position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
Keros Therapeutics appointed Anne Prener, M.D., Ph.D., as a director effective July 1, 2026. Dr. Prener brings significant clinical development and executive leadership experience to the Board. Her compensation package includes initial and annual equity grants totaling $300,000 in grant-date fair value plus a $41,500 annual cash retainer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-25
Item 5.02
Craig Harris was appointed as a director of Kinetik Holdings Inc., effective June 23, 2026, increasing the Board size from 10 to 11 directors. Harris brings 30+ years of energy industry experience and senior leadership roles at Blackstone, Enable Midstream Partners, and El Paso Corporation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-25
Item 5.02
Worthington Steel appointed Gwen Joseph as Corporate Controller and Principal Accounting Officer effective June 23, 2026, with a compensation package of $255,000 base salary, 50% target cash incentive, and $200,000 equity award.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-24
The 6-K discloses the Board's approval on June 22, 2026, of Dr. Cheng Chen's appointment as an independent director, effective immediately. Dr. Chen will also serve on the audit committee, compensation committee, and corporate governance and nominating committee. This is a clear executive/director appointment that would affect a reasonable investor's assessment of the company's governance and board composition.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-24
EX-99.2
Sanofi announced the appointment of Paulo Fontoura as Executive Vice President, Global Head of Research & Development Pharma, effective September 1, 2026, with membership on the Executive Committee reporting to the CEO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-24
Item 5.02
Three new directors—Randall Bort, Keith Covington, and Elizabeth Marcellino—were appointed to the board on June 22, 2026, in connection with the company's IPO, with Bort chairing the Audit Committee and Marcellino chairing the Compensation Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-24
Item 5.02
The filing discloses two board-level events: the resignation of Sarfraz Maredia on June 17, 2026, and the appointment of Andreas Lieber on June 22, 2026, to fill the vacancy. While both events are disclosed, the principal action emphasized in the Item 5.02 disclosure and press release is the appointment of Lieber, a director with substantial operational and strategic experience (COO of Shippo, interim CEO of Postmates, roles at Uber and Pinterest). The appointment is material to investors as it reflects board composition changes and brings relevant expertise in logistics and platform scaling to a company expanding beyond sidewalk delivery into hospital robotics and infrastructure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-24
Item 5.02
Wilco 63 Corporation appointed four independent directors—James Reynolds, Sriram Ramanathan, Matt Swann, and Joseph Bradley—to its board in connection with the IPO closing on June 22, 2026, with assignments to various board committees under a three-class board structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-24
Item 5.02
Four directors—R. Greg Smith, Andrew Clark, Harvin Moore, and Aruna Viswanathan—were appointed to the board on June 17, 2026, in connection with the Company's IPO, with assignments to the Audit and Compensation committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-24
Item 7.01
Mark Fioravanti was appointed as Non-Executive Chairman of the Board effective immediately following the Annual Meeting on June 22, 2026, succeeding Denise W. Warren in the Chairman role.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-24
EX-99.1
The exhibit announces Julie Kim's appointment as Representative Director, President and CEO of Takeda following shareholder election and Board approval at the 150th Annual General Meeting. This is a material executive appointment of the company's chief executive officer, the most senior operational role. The disclosure also includes the concurrent retirement of former CEO Christophe Weber and appointments of three new external directors (Broussard, Kimura, Stoffels) and reassignments of existing directors to new committee roles, all effective June 24, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-24
Item 8.01
The filing discloses the appointment of Alex Hastie, Ph.D. as Chief Scientific Officer of Bionano Genomics, effective July 20, 2026. This is a material executive appointment to a senior leadership role responsible for leading the company's global scientific strategy, innovation roadmap, and research initiatives. The appointment is material because it involves a key executive position at a company in the genomics sector where scientific leadership directly impacts competitive positioning and product development strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-24
Item 5.02
Richard Fang, Ph.D. was appointed as Interim CEO effective June 18, 2026, following the planned departure of Patrick NJ Schnegelsberg. Dr. Fang will receive an annual salary of $400,000 and brings relevant executive experience to the role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-24
Item 5.02
Ryan Cotterman was appointed as Vice President, Chief Accounting Officer and principal accounting officer of Ingevity Corporation on June 22, 2026. The disclosure centers on the appointment of a named executive officer to a principal accounting role, with detailed compensation terms including base salary ($345,000), bonus target (40%), long-term incentive opportunity (65%), sign-on bonus ($40,000), and equity award ($150,000 RSUs). This is a material executive appointment affecting the registrant's accounting leadership and financial reporting oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-23
Item 5.02
Nike announced the appointment of David M. Denton as Executive Vice President and Chief Financial Officer, effective August 17, 2026, replacing Matthew Friend. Denton's compensation package includes a $1.45M base salary, $11.5M long-term incentive target, and a $7.25M new-hire cash award.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-06-23
Item 5.02
F5, Inc. appointed Gavin Munroe as a director effective June 17, 2026, with assignment to the Risk and Audit Committees. The appointment includes compensatory arrangements comprising an annual retainer of $60,000, committee fees of $20,000 each, and a restricted stock unit grant valued at $275,000.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-23
EX-99.1
The exhibit announces the appointment of Ms. Qianfei Chang as an independent director, audit committee chairman, and member of two other board committees, effective July 1, 2026. While the disclosure also mentions Mr. Heping Feng's resignation, the principal disclosed action is the appointment of a new director with significant financial and audit expertise to key governance roles. This is material to investors as it affects board composition and oversight functions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
Five new trustees were elected effective as of the company's emergence from bankruptcy: Jonathan Heller, Jonathan Kolatch, William A. Lamkin, Adam D. Portnoy, and Irvin Schlussel. This represents a complete board reconstitution following the Chapter 11 reorganization, with the new trustees assigned to various committees and compensation arrangements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
Bartolomeo A. Frabotta was appointed as Chief Operating Officer of Clean Energy Fuels Corp. effective June 23, 2026, representing a material promotion from his prior role as Group Vice President of Operations. The appointment includes a detailed employment agreement with base salary of $545,056, 100% bonus eligibility, 50,000 RSU equity grants, and severance terms, and makes him a named executive officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
The filing discloses the election of three new directors to Bank First Corporation's Board of Directors on June 16, 2026: SriRaj Kantamneni, Tracy C. Pearson, and William J. Ring, each for three-year terms. This is a clear executive appointment event involving multiple board-level positions, which is material to investors' assessment of corporate governance and leadership composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
The Board appointed Daniel M. Skovronsky, M.D., Ph.D., to serve as a director effective June 16, 2026, increasing the Board size from nine to ten members. The disclosure centers on the appointment of a new director with relevant scientific and pharmaceutical R&D expertise, making this a clear exec_appointment event. The appointment is material as it represents a change in the composition of the Board of Directors.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-23
The 6-K announces the appointment of two directors, Mr. Erez Wiener and Mr. Daniel Schutz, effective July 1, 2026. This is a clear executive/governance appointment. The disclosure includes detailed biographical information for both appointees, including Wiener's prior service as CEO of the Company and Schutz's family relationship to the CEO and controlling shareholder Joseph Williger, making this material to investors' assessment of board composition and potential conflicts of interest.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-23
Item 5.02
In connection with the merger transaction, Oien was appointed as President and principal executive officer of Boundless Bio, replacing departing CEO Hornby, along with compensatory arrangements including transaction bonuses and acceleration of stock options.
View raw filing on EDGAR →